This study aimed to investigate the bioequivalence of 2 formulations of gliclazide modified-release tablets 60 mg in 48 healthy Caucasian volunteers under fasting conditions. A test product, Gliclazide MR (Ranbaxy Laboratories Limited, now Sun Pharmaceutical Industries, India), was compared with a reference product, Diamicron MR (Servier, France). The study was performed under a single-dose, 2-treatment, 2-period, 2-sequence crossover design in a fasted condition with a washout period of 21 days. Blood samples were collected for 96 hours after drug administration. Drug plasma concentrations were determined by a liquid chromatography-tandem mass spectrometry method. Analysis of pharmacokinetic characteristics was based on a noncompartmental model. The logarithmically transformed data of C max and AUC were analyzed for 90% confidence intervals using analysis of variance. There was no significant difference in pharmacokinetic characteristics between the products, and the 90% confidence intervals were within the acceptance range of 80.00%-125.00%. The investigated products were bioequivalent under fasted conditions.
The whole world faces an increased incidence of type 2 diabetes because of the occidental lifestyle, population aging, urbanization, resulting changes in diet, adoption of a sedentary lifestyle, and the development of obesity. The incidence of type 2 diabetes has increased dramatically. Diabetes mellitus is associated with a large number of chronic complications whose end result is decreased quality of life and premature mortality. 1, 2 The therapeutic guidelines developed by various international organizations are based on numerous clinical trials that followed different treatment modalities in type 2 diabetes, aiming to achieve therapeutic targets. Treatment of type 2 diabetes mellitus may include nonpharmacological treatment (diet and exercise) and medication. 1 Sulfonylureas are the most frequently used oral hypoglycemic agents. Trials of gliclazide modified release in varied populations have yielded very acceptable clinical results that support its first-line use in type 2 diabetes, including obese, elderly, and patients with mild to moderate renal insufficiency. The simplicity of its dose regimen and its efficacy and tolerance profile may significantly contribute to improving compliance. 3 Gliclazide reduces blood glucose levels by stimulating insulin secretion from the β-cells of the islets of Langerhans. Gliclazide shows high affinity, strong selectivity, and reversible binding to the β-cell KATP channels, with a low affinity for cardiac and vascular KATP channels. Increased postprandial insulin and C-peptide secretion persist after 2 years of treatment. Gliclazide also has extrapancreatic effects and hemovascular properties. 4 The drug is insoluble under acidic conditions in the stomach, and its solubility increases with increasing pH in the intestinal region. Drug absorption is also controlled by the ability of the drug to be released from the dosage form. 5 Modified-release dosage forms of gliclazide are designed so that the hydration of the tablet induces formation of a gel to activate drug release. Plasma levels are progressively increasing and from the 6th to the 12th hours after administration, a plateau-shaped curve can be observed. Intraindividual variability is observed to be low. Gliclazide is completely absorbed. Food intake does not affect the rate or degree of absorption. 6 A low apparent volume of distribution is probably reflected in the high degree of gliclazide binding to proteins (approximately 94%). 7 Gliclazide is mainly metabolized in the liver. Metabolites and conjugates are eliminated primarily by the kidneys (60%-70%) and also in the feces (10%-20%). Less than 1% of the unchanged form is found in urine. No active metabolites have been detected in plasma. At least 8 metabolites have been identified in urine. Tolylmethyl hydroxylation followed by oxidation to the corresponding carboxylic acid is the major metabolic pathway of gliclazide. Hydroxylation of the azabicyclo-octyl moiety has the potential to form 7 monohydroxylated metabolites. There is no evidence that transporters are involved in gliclazide disposition. 6, 8 Cytochrome P450 2C9 (CYP2C9) is the major contributor to gliclazide metabolic clearance, although contributions of CYP2C19 and possibly CYP2C18 cannot be excluded. CYP2C9 enzyme is encoded by CYP2C9 polymorphic gene with 29 variant alleles. CYP2C9 polymorphism along with additional pharmacodynamic factors could account for individual differences in the hypoglycemic effects of gliclazide. 8, 9 The elimination half-life of gliclazide varies between 8.1 and 20.5 hours. 7 The relationship between the dose administered, ranging up to 120 mg, and the area under the concentration-time curve is linear. 6 Gliclazide modified release has been shown to have predictable and reproducible release of gliclazide and maintains effective plasma concentrations over a 24-hour period. 6 The glycemic profile was improved over 24 hours after medium-term treatment (10 weeks) of type 2 diabetic patients, with gliclazide modified release given once daily, with a decrease of 1% of the mean HbA 1c and improvement in patient compliance. 10 A new formulation has been developed that will be evaluated for bioequivalence with the product already on the market.
Methods
This research was carried out in accordance with the basic principles defined in US 21 CFR Part 320, the ICH E6 (R1) (CPMP/ICH/135/95), "Guideline for Good Clinical Practice," and the principles enunciated in the Declaration of Helsinki. This research was also carried out in accordance with the "Guideline on the Investigation of Bioequivalence," by the European Agency for the Evaluation of Medicinal Products.
The protocol was approved by the National Agency for Medicines and Medical Devices, Romania, and the Ethics Committee of the University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj Napoca, Romania.
The study was conducted at the Clinical Pharmacology and Pharmacokinetics Department of Terapia SA, Romania.
Study Design
The relative bioavailability of the 2 treatments (one test and one reference formulation as modified-release tablets containing gliclazide 60 mg) was determined in an open-label, balanced, randomized, 2-period, 2-sequence, single-dose crossover study in fasting conditions. The washout period was 21 days.
Volunteers
The investigator accepted the volunteers in the study after examining their health by medical history, physical examination, and routine blood test and determining they were negative for hepatitis B surface antigen, anti-hepatitis C antibody, and anti-HIV. All participants were declared healthy volunteers aged between 19 and 40 years and with a body mass index within 18.67-28.91 kg/m 2 . Volunteers with known contraindication or hypersensitivity to gliclazide were excluded, as were those with a known history of drug dependence, excessive alcohol intake, or who were regular cigarette smokers who smoked more than 10 cigarettes daily. No drug was allowed 28 days before the study period to avoid the effect of inducting hepatic enzymes or 14 days before the study period to avoid the effect of inhibiting hepatic metabolizing enzymes and the risk of drug interaction. All volunteers were clearly informed about the methods and conditions of the study, including rights, obligations, and possible side effects, and signed informed consent was obtained from all volunteers before entering the study.
For female volunteers, a pregnancy test was carried out at screening, at admission in each study period, and at the end of the study.
Forty-eight subjects were enrolled in the study. The number of subjects was planned based on the following assumptions: test/reference ratio in the range of 95%-105%, an expected intrasubject coefficient of variation of approximately 30%, power of 80%, and possible dropouts and/or withdrawals. Forty-one subjects finalized the study.
Drug Administration
Test product was gliclazide 60-mg modified-release tablets, manufactured by Ranbaxy Laboratories Limited, now Sun Pharmaceutical Industries, India (Lot 2502717, expiration March 2015), and reference product was Diamicron modified-release tablets (containing gliclazide 60 mg), manufactured by Les Laboratoires Servier Industrie, France (Lot 917799, expiration August 2015).
In each period subjects alternatively received the experimental formulation (T) or the reference formulation (R), as per the generated randomization list.
Following an overnight fast of at least 10 hours, the drug product was administered with 240 mL of 20% glucose solution at ambient temperature under supervision of trained study personnel. No food was allowed for at least 4 hours postdose. Approximately 60 mL of 20% glucose solution was administered approximately every 15 minutes for up to 4 hours postdose to prevent hypoglycemia. All subjects were dosed while seated and were instructed to remain seated or semisupine for the first 2 hours following each drug administration.
Drinking water was not allowed from 1 hour before dosing until 2 hours postdose. During housing subjects received standard meals.
Safety
Safety evaluation was not an objective of this study; however, the study subjects were monitored throughout the study period for adverse events. Subjects were specifically asked about any adverse events at admission, prior to dosing, and approximately 4, 8, 12, 24, 36, 48, 72, and 96 hours postdose in each period. The principal investigator or a subinvestigator was available at the site of investigation at least 24 hour postdose during each period.
Clinical examination, hematology, biochemistry, pregnancy test (for female volunteers only), and urine analysis were repeated at the end of the study.
Sitting blood pressure, radial pulse, and axillary body temperature were measured predose and 4, 8, 12, 24, 36, 48, 72, and 96 hours after administration of the study drug, in each period.
As for the administered products, hypoglycemia has been reported as an adverse event, and for safety reasons blood glucose levels were measured prior to dosing and 1, 2, 3, 6, and 7 hours postdose in each period of the study.
Blood Sample Collection
Blood samples of 4 mL each were collected predose (in double volume) and 1, 2, 3, 4, 5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, 13, 13.5, 14, 15, 16, 20, 24, 36, 48, 72, and 96 hours postdose in each period. The samples were collected in K 3 -ethylenediaminetetraacetic acid vacutainers during the course of the study either through an indwelling cannula placed in forearm veins or through venous puncture.
Bioanalytical Method
Blood samples were centrifuged for 15 minutes under refrigeration at 4000 rpm, and the plasma was taken and immediately kept at −50°C until assay.
Plasma samples were assayed for gliclazide using a liquid chromatography-tandem mass spectrometry validated method using high-pressure liquid chromatography (HPLC) Agilent 1200 from Agilent Technologies and MS API 3200 from Applied Biosystem MDS SCIEX. For sample preparation, more than 50 μL of internal standard dilution (Gliclazide D4, approximately 1500 ng/mL) was added to 150 μL of plasma and 150 μL water and vortexed. The samples were applied to a solid-phase extraction cartridge (Cleanert PEP-H 30 mg/mL), previously conditioned with 1 mL of methanol and 1 mL of water. Gliclazide was extracted using methanol, evaporated under nitrogen stream, and the residue was reconstituted with 200 μL of mobile phase (water/methanol/formic acid 98%-100% [100:900:0.01 v/v/v]). The extracted samples were injected into the HPLC with the column BDS HY-PERSIL C18, 50 × 4.6 mm, 3 μm. The flow rate was 0.800 mL/min, the injection volume was 10 μL, and the run time was 2.5 minutes.
Mass spectrometry was performed in the positiveion multiple reaction-monitoring mode with m/z transitions of 324.10→127.10 for gliclazide and 328.10→127.10 for the internal standard.
Analyst software version 1.4.2 was used to determine peak areas of gliclazide and the internal standard. Subject sample concentrations were calculated from peak area ratios.
Calibration curves were linear over plasma gliclazide concentration ranges of 5.00 to 5016.48 ng/mL.
During validation, the between-run accuracy was 90.53% to 110.14%, between-run precision was 1.83% to 4.69%, within-run accuracy was 89.10% to 114.98%, and within-run precision was 0.96% to 4.38%.
Statistical Methods and Data Analysis Pharmacokinetic Analysis
The following pharmacokinetic parameters, C max , T max , AUC 0-t , AUC 0-Ý , AUC % Extrap, and T 1/2 , were calculated using noncompartmental analysis for gliclazide using WinNonlin PK software version 5.2.
Statistical Analysis for Bioequivalence
The statistical analysis was performed using SAS software version 9.1.3.
The log-transformed pharmacokinetic parameters (C max , AUC 0-t , and AUC 0-Ý ) were analyzed using type III sum of squares from analysis of variance (ANOVA). Each ANOVA included calculating the least-squares mean (LSM), the difference between the adjusted formulation means and the standard error associated with the difference.
The 90% confidence intervals for the ratio of the test (T) and reference (R) product averages were calculated for gliclazide by first calculating the 90% confidence interval for the differences in the averages (LSM) of the log-transformed data and then taking the antilog of the obtained confidence limits. The comparison of interest is test versus reference, so the ratios were of the form: test/reference. Ratios of the means were calculated using the antilog of the differences of LSMs for log-transformed C max , AUC 0-t , and AUC 0-Ý .
The 90% confidence interval for the ratio of test (T) and reference (R) product averages for pharmacokinetic parameters C max and AUC 0-t from analysis of logtransformed data should be between 80% and 125%.
Results
The study was conducted on a Caucasian human population. All subjects were similar with respect to age, weight, and height distribution. The mean age, mean weight, mean height, and mean body mass index of the study subjects were 23 years (range, 19 to 40 years), 71.3 kg (range, 48 to 108 kg), 174.8 cm (range, 155 to 197 cm), and 23.1 kg/m 2 (18.7 to 28.9 kg/m 2 ), respectively.
The following not-serious adverse events were reported in this study: hypoglycemia, diarrheic stools, acute pharyngitis, diarrheic syndrome, nausea, dizziness, odontalgia, flu-like syndrome, acute gastroenterocolitis, headache, vomiting, proteinuria, increased lactate dehydrogenase, urinary infection, increased direct bilirubin, increased aspartate aminotransferase, increased serum glucose, and increased total leukocytes. The analysis of adverse events by treatment group is presented in Table 1 .
The plots of gliclazide plasma concentrations versus time under the fasted condition are shown in Figure 1 , and pharmacokinetic characteristics are summarized in Table 2 . The test product gave comparable values for C max and AUC 0-t . The ratios of LSMs (with 90% confidence intervals) for the pharmacokinetic parameters C max , AUC 0-t , and AUC 0-Ý for gliclazide were 104.58% (96.42%-113.42%), 99.55% (96.21%-103.01%), and 99.43% (96.16%-102.81%), respectively.
Discussion
The administration of the glucose solution was decided to reduce the risk of hypoglycemia, which has been reported for sulfonylureas, and to monitor glucose levels periodically. It was evaluated not to have any interaction with gliclazide.
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Absorption was not influenced by administration of food, and it was reported that there were no significant differences in values of C max , AUC 0-t, AUC 0-Ý , and T 1/2 between the fasted and fed states. It is considered that the administration of glucose solution has no significant impact on the fasted state and the study results. 6 Even if the current study had not been intended for pharmacological evaluation, the tested product is intended for patients with glucose levels higher than the reference ranges.
Adverse events observed in the study are considered unlikely to have had any impact on the safety of the subjects. T, test product, which is gliclazide 60 mg modified-release tablets; R, reference product, which is Diamicron modified-release tablets.
The mean values for the pharmacokinetic parameters were similar for the test and reference products. The test product gave a slightly lower AUC with higher C max and shorter T max than the reference product; however, these were not statistically significant. The range of T max values of the test product and reference product were 4-16 and 4-20 hours, respectively. The median T max of both the test and reference products was 8.5 hours. The median T max obtained from this study was similar and comparable to values reported earlier. 6 The T 1/2 values of the test product and reference product were similar and comparable to the values reported previously. 7 For all evaluated pharmacokinetic parameters no significant differences between the products under fasted condition were found.
The 90% confidence intervals for the ratio of test (T) and reference (R) product averages derived from the analysis of log-transformed pharmacokinetic parameters C max and AUC 0-t were within the 80.00%-125.00% acceptance range.
Based on these results, gliclazide 60-mg modifiedrelease tablets manufactured by Ranbaxy Laboratories Limited, now Sun Pharmaceutical Industries, India, and Diamicron modified-release tablets (containing gliclazide 60 mg) manufactured by Les Laboratoires Servier Industrie, France, are bioequivalent in healthy human adult subjects under fasting conditions. The products can be interchangeable.
Insulin and oral hypoglycemic agents are reported as generally available in only a minority of low-income countries. Policy and program interventions are needed to improve equitable access. 2 Considering the results of the study by registration of generic products, more patients would have access to appropriate treatment.
By using modified-release tablets, the effective concentrations are maintained for 24 hours, improving patient compliance with the treatment.
Conclusion
Gliclazide 60 mg modified-release tablets manufactured by Ranbaxy Laboratories Limited, now Sun Pharmaceutical Industries, India, and Diamicron modifiedrelease tablets (containing gliclazide 60 mg) manufactured by Les Laboratoires Servier Industrie, France,are bioequivalent in healthy human adult subjects under fasting conditions.
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